Text Size

A Linkage and Association Study in Pulmonary Fibrosis (GWAS)

This study is currently recruiting participants.
Verified February 2010 by National Jewish Health
Sponsor:
Collaborators:
University of Colorado, Denver
Vanderbilt University
Landspitali University Hospital
Information provided by (Responsible Party):
National Jewish Health
ClinicalTrials.gov Identifier:
NCT01088217
First received: March 15, 2010
Last updated: March 14, 2012
Last verified: February 2010
History of Changes

March 15, 2010
March 14, 2012
July 2008
July 2018   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01088217 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Linkage and Association Study in Pulmonary Fibrosis
GWAS in Fibrosing Interstitial Lung Disease

The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis. Finding the genes that cause pulmonary fibrosis is the first step at developing better methods for early diagnosis and improved treatment for pulmonary fibrosis. The overall hypothesis is that inherited genetic factors predispose individuals to develop pulmonary fibrosis.

Familial Pulmonary Fibrosis (FPF) is a sub-category of the idiopathic interstitial pneumonias (IIPs). IIPs are progressive lung conditions, with limited treatment options and unknown etiology. Though the IIPs have been associated with both genetic risk factors and environmental exposures, the molecular mechanism underlying disease progression remain poorly understood. This investigation seeks to identify a group of genetic loci that play a role in the development of familial interstitial pneumonia (FIP) or FPF, where 2 or more cases of IIP are seen within a family.
Observational
Observational Model: Family-Based
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Description:

whole blood, serum, plasma, lung tissue, DNA, RNA
Non-Probability Sample

Families with two or more individuals diagnosed with Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic Interstitial Pneumonia (IIP)
  • Idiopathic Pulmonary Fibrosis
  • Familial Pulmonary Fibrosis
  • Idiopathic Interstitial Pneumonia
  • Familial Interstitial Pneumonia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
8000
July 2018
July 2018   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Two or more family members with a clinical diagnosis of Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic Interstitial Pneumonia (IIP)
  • Additional family members may be eligible to participate if two family members are suspected of or diagnosed as having Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic Interstitial Pneumonia (IIP)

Exclusion Criteria:

  • Individuals whose pulmonary fibrosis is due to a known cause rather than idiopathic
  • Individuals whose pulmonary fibrosis is due to a broader genetic syndrome
Both
7 Years and older
No
Contact: Janet Talbert, MS, CGC 800-423-8891 ext 1022 talbertj@njhealth.org
United States,   Iceland
 
NCT01088217
1RO1HL097163
No
National Jewish Health
National Jewish Health
  • University of Colorado, Denver
  • Vanderbilt University
  • Landspitali University Hospital
Principal Investigator: David A. Schwartz, MD University of Colorado Denver; National Jewish Health
National Jewish Health
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP